Claims for Patent: 8,574,577

Summary for Patent: 8,574,577

Title:	VEGF antibodies comprising modular recognition domains
Abstract:	Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described.
Inventor(s):	Barbas, III; Carlos F. (La Jolla, CA)
Assignee:	The Scripps Research Institute (La Jolla, CA)
Application Number:	13/135,788
Patent Claims:	1. A complex comprising an antibody and at least one modular recognition domain (MRD), wherein the antibody binds to VEGF, wherein the MRD competitively inhibits binding of angiopoietin-2 (Ang2) to a polypeptide consisting of the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:21, and wherein the complex is capable of binding to VEGF and Ang2 simultaneously. 2. The complex of claim 1, wherein the VEGF is human. 3. The complex of claim 1, wherein the antibody is chimeric, humanized, or human. 4. The complex of claim 3, wherein the antibody is humanized. 5. The complex of claim 1, wherein the antibody is bevacizumab. 6. The complex of claim 1, wherein an MRD is located on a terminus selected from the group consisting of (a) the N-terminus of the antibody heavy chain, (b) the N-terminus of the antibody light chain, (c) the C-terminus of the antibody heavy chain, and (d) the C-terminus of the antibody light chain. 7. The complex of claim 6, wherein a first MRD is located on (c) the C-terminus of the antibody heavy chain and a second MRD is located on (d) the C-terminus of the antibody light chain. 8. The complex of claim 6, wherein the antibody and the MRD are operably linked through a linker peptide. 9. The complex of claim 8, wherein the linker comprises a sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:19. 10. The complex of claim 1, wherein the Ang2-binding MRD comprises a sequence selected from the group consisting of: SEQ ID NOs:7-12, SEQ ID NOs:20-34, and SEQ ID NO:57. 11. The complex of claim 10, wherein the Ang2-binding MRD comprises the sequence of SEQ ID NO:8. 12. The complex of claim 1 , wherein the Ang2-binding MRD competitively inhibits binding to Ang2 of an MRD comprising the sequence of SEQ ID NO:8. 13. The complex of claim 1, further comprising a second MRD. 14. The complex of claim 13, wherein the second MRD binds to insulin-like growth factor-I receptor (IGF-IR), and competitively inhibits binding to IGF-1R to a polypeptide consisting of the amino acid sequence of SEQ ID NO:14. 15. The complex of claim 14, wherein the Ang2-binding MRD is located on the C-terminus of the antibody heavy chain and the IGF-IR-binding MRD is located on a terminus selected from the group consisting of (a) the C-terminus of the antibody heavy chain, (b) the N-terminus of the antibody heavy chain, (c) the C-terminus of the antibody light chain, and (d) the N-terminus of the antibody light chain. 16. The complex of claim 14, wherein the Ang2-binding MRD is located on the N-terminus of the antibody heavy chain and the IGF-IR-binding MRD is located on a terminus selected from the group consisting of (a) the C-terminus of the antibody heavy chain, (b) the N-terminus of the antibody heavy chain, (c) the C-terminus of the antibody light chain, and (d) on the N-terminus of the antibody light chain. 17. The complex of claim 14, wherein the Ang2-binding MRD is located on the C-terminus of the antibody light chain and the IGF-IR-binding MRD is located on a terminus selected from the group consisting of (a) the C-terminus of the antibody heavy chain, (b) the N-terminus of the antibody heavy chain, (c) the C-terminus of the antibody light chain, and (d) the N-terminus of the antibody light chain. 18. The complex of claim 14, wherein the Ang2-binding MRD is located on the N-terminus of the antibody light chain and the IGF-IR-binding MRD is located on a terminus selected from the group consisting of (a) the C-terminus of the antibody heavy chain, (b) the N-terminus of the antibody heavy chain, (c) the C-terminus of the antibody light chain, and (d) the N-terminus of the antibody light chain. 19. The complex of claim 14, wherein the antibody and (a) the Ang2-binding MRD, (b) the IGF-1R-binding MRD or (c) the Ang2-binding MRD and the IGF1R-binding MRD are operably linked through a linker peptide. 20. The complex of claim 19, wherein the linker comprises a sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:19. 21. The complex of claim 14, wherein the antibody is capable of binding to VEGF, Ang2, and IGF-IR simultaneously. 22. The complex of claim 1, wherein the antibody exhibits ADCC activity. 23. A pharmaceutical composition comprising the complex of claim 1. 24. A method for inhibiting the growth of a cell expressing VEGF comprising contacting the cell with the complex of claim 1. 25. A method for inhibiting angiogenesis in a patient comprising administering to said patient a therapeutically effective amount of the complex of claim 1. 26. A method for treating a patient having cancer comprising administering to said patient a therapeutically effective amount of the complex of claim 1. 27. The method of claim 25 or 26, further comprising administering a second therapeutic agent to the patient. 28. The method of claim 27, wherein the second therapeutic agent is a chemotherapeutic agent. 29. The method of claim 28, wherein the chemotherapeutic agent is a taxane-based or platinum-based therapeutic agent.

Details for Patent 8,574,577

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2028-01-03